Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

DSpace/Manakin Repository

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Citable link to this page

 

 
Title: Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
Author: Yuan, Jianda; Zhou, Jun; Dong, Zhiwan; Tandon, Sapna; Kuk, Deborah; Panageas, Katherine S; Wong, Philip; Wolchok, Jedd D; Hodi, F Stephen

Note: Order does not necessarily reflect citation order of authors.

Citation: Yuan, Jianda, Jun Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S Panageas, Philip Wong, Jedd D Wolchok, and F Stephen Hodi. 2013. “Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.” Journal for Immunotherapy of Cancer 1 (Suppl 1): P247. doi:10.1186/2051-1426-1-S1-P247. http://dx.doi.org/10.1186/2051-1426-1-S1-P247.
Full Text & Related Files:
Abstract:
Published Version: doi:10.1186/2051-1426-1-S1-P247
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991109/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407008
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters